Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research on MSN3h
Wall Street Analysts Predict a 44.2% Upside in Novo Nordisk (NVO): Here's What You Should KnowShares of Novo Nordisk (NVO) have gained 2.9% over the past four weeks to close the last trading session at $80.15, but there could still be a solid upside left in the stock if short-term price ...
San Francisco, California-- (Newsfile Corp. - March 17, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Zacks Investment Research on MSN5d
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Zacks.com on MSN6d
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity StudyNovo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback